Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Large Cap

Large Cap

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News
  • Top Stories

Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute

By Vandana Singh
May 20, 2:18 PM
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.

AZN

Read More
2 minute read
  • Buybacks
  • Dividends
  • Earnings
  • Equities
  • Guidance
  • Large Cap
  • News

What’s Going On With European Airline Ryanair’s Stock Today?

By Lekha Gupta
May 20, 1:34 PM
Ryanair Holdings reported full-year results with 25% revenue growth, 34% net profit increase, and plans for 8% traffic growth in FY25.

BA

Read More
2 minute read
  • Commodities
  • Econ #s
  • Equities
  • ETFs
  • Federal Reserve
  • Intraday Update
  • Large Cap
  • Macro Notification
  • Market Summary
  • Mid Cap
  • Sector ETFs
  • Small Cap
  • Tech
  • Top Stories
  • Travel
  • Treasuries

Stocks, Gold Reach New Record Highs, Cruise Stocks Rally, GameStop Sinks: What’s Driving Markets Monday?

By Piero Cingari
May 20, 1:34 PM
Wall Street rallies on Monday as major US indices reach fresh record highs. Metal commodities surge, Treasury yields stay stable. Cruise stocks soar.

CCL

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Broad U.S. Equity ETFs
  • Equities
  • ETFs
  • Large Cap
  • Markets
  • Tech
  • Top Stories

Dow To Reach 60,000, S&P 500 To Hit 8,000 By 2030 In Wall Street Veteran’s ‘Roaring 2020s Scenario’

By Piero Cingari
May 20, 12:54 PM
Dow Jones hits 40,000 for the first time ever. Analyst Ed Yardeni forecasts the Dow to reach 60,000 by 2030 and S&P 500 to climb to 8,000. Strong earnings growth fuels optimism.

DIA

Read More
2 minute read
  • Equities
  • Large Cap
  • M&A
  • News

$60B TAM Target: CyberArk Bolsters Machine Identity Solutions With Venafi Acquisition

By Lekha Gupta
May 20, 11:49 AM
CyberArk Software Ltd. acquires Venafi from Thoma Bravo for $1.54 billion, adding $150 million in ARR and expanding TAM from $50 billion to $60 billion.

CIBR

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Top Stories

Gilead’s Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch

By Vandana Singh
May 20, 9:36 AM
Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant improvements in cholestasis markers and pruritus.

GILD

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Top Stories

Genetic Profile Key To Novo Nordisk’s Wegovy’s Weight-Loss Effectiveness, Study Reveals

By Vandana Singh
May 20, 9:34 AM
Certain genes may predict strong responses to Novo Nordisk's Wegovy (semaglutide) in obesity treatment, with patients showing significant weight loss linked to a "hungry gut" genetic profile. This finding could enhance personalized obesity care, optimizing treatment outcomes.

NVO

Read More
4 minute read
  • Equities
  • Large Cap
  • News
  • Tech
  • Top Stories

What’s New In Consumer Tech World Last Week? News That You Should Know (May 12-May 19, 2024)

By Lekha Gupta
May 20, 7:31 AM
Chinese chipmakers make headway in producing high bandwidth memory semiconductors, Zuckerberg celebrates 40th birthday on superyacht, Google may revive Google Glass, and Musk expresses skepticism about OpenAI's AI model development.

AAPL

Read More
1 minute read
  • Equities
  • Large Cap
  • Movers
  • News
  • Top Stories

MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio?

By Lekha Gupta
May 19, 7:27 PM
Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets & more positive news.

AIG

Read More
1 minute read
  • Large Cap
  • Movers
  • News
  • Top Stories

Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)

By Lekha Gupta
May 19, 7:17 PM
Last week, these 10 large-cap stocks had the worst performance. NICE, PBR, FIX, LI, MLM, VMC, BMRN, EDU, GFI, MUFG all saw significant decreases.

BMRN

Posts pagination

Previous 1 … 24 25 26 … 437 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service